In addition, in vivo data utilizing SKOV-3 xenografts suggested that cognate ligand activation of PXR promoted tumor growth by significantly inactivating and decreasing cytotoxic drug concentrations via upregulation of PXR-mediated drug-metabolizing enzymes CYP2B6, CYP3A4 and UDP glucuronosyltransferase 1A1 (UGT1A1)[33]. Here, CYP3A4 is linked to neoplasm.